Free Delivery World Wide* Learn more
Loved by our Customers. 5000+ Reviews
Free Returns and Free Shipping
Sale!
Sale!
Syringes | Needles | Accessories
Exel 3ml (3cc) Syringe/Needle Combination Luer-Slip Tip 20G x 1″ (Box of 100)
$25.38
Syringes | Needles | Accessories
BD Blunt Fill Needle with 5 Micron Filter 18G x 1 1/2″ – Sterile (10 pack)
$8.84
Retatrutide is a breakthrough weight loss drug in development, showing promising results in targeting multiple pathways for effective weight management.
What is Retatrutide?
Retatrutide, a synthetic peptide created by Eli Lilly, is also known by its development code LY3437943. This peptide acts as a triple receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors [1].
Both GLP-1 and GIP are incretin hormones that stimulate insulin secretion and modulate immune responses. Moreover, the activation of GCG receptors by retatrutide is thought to boost metabolic rate and increase energy expenditure [2].
This cutting-edge compound is being explored for its role in controlling blood glucose levels and aiding in weight loss [3].
Important details for researchers:
- Developed by Eli Lilly, retatrutide is a synthetic peptide based on the structure of GIP and is composed of 39 amino acids. While it predominantly targets GIP receptors, it has been engineered to also activate GLP-1 and GCG receptors [4].
- Retatrutide features a structural modification with a fatty acid component, which enhances its stability and prolongs its activity in the body, allowing for once-weekly dosing [5].
- Currently, retatrutide is undergoing evaluation in clinical trials for its safety and effectiveness in treating obesity, both in individuals with and without type 2 diabetes (T2D), as part of Eli Lilly’s TRIUMPH phase-3 clinical program [3].
- Initial study results have indicated positive outcomes for both glycemic control and weight loss [6, 7].
Although it has not yet been approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA), retatrutide is available to qualified researchers as a reference material for studying the therapeutic potential of this triple receptor agonist.
Retatrutide Prescription for Weight Loss & Obesity
For millions struggling with obesity and have been searching for Retatrutide for sale (LY3437943), this represents the most exciting advancement in metabolic medicine. This triple-receptor agonist uniquely targets GLP-1, GIP, and glucagon pathways to suppress appetite, boost fat burning, and improve insulin sensitivity simultaneously. Early trials show unprecedented 24% average body weight reduction—outperforming current leaders like Wegovy and Mounjaro 110.
What Is Retatrutide?
Developed by Eli Lilly, Retatrutide is the first “triple G” obesity drug designed to mimic three gut hormones:
-
GLP-1: Slows digestion and reduces hunger
-
GIP: Enhances insulin secretion and fat metabolism
-
Glucagon: Increases energy expenditure by burning stored fat 14
Unlike single-action drugs (e.g., Semaglutide) or dual agonists (e.g., Tirzepatide), this triple mechanism offers synergistic metabolic benefits, positioning it as a potential game-changer 11.
Results of the Phase 2 Trial on Retatrutide for Obesity
The landmark 48-week trial published in The New England Journal of Medicine revealed:
-
24.2% body weight loss (avg. 58 lbs) in obese/overweight adults
-
17.5% reduction achieved within just 24 weeks
-
Significant improvements in blood sugar, liver fat, and cardiovascular markers 1102
These results surpassed all existing weight loss medications, with participants continuing to lose weight throughout the study period.
Is Retatrutide More Effective Than Other Weight Loss Drugs?
| Drug | Mechanism | Avg. Weight Loss | Key Limitations | |
|---|---|---|---|---|
| Retatrutide | Triple agonist (GLP-1+GIP+Glucagon) | 24% at 48 weeks | Not yet FDA-approved | |
| Tirzepatide (Mounjaro®) | Dual agonist (GLP-1+GIP) | 22.5% | Limited effect on fat metabolism | |
| Semaglutide (Wegovy®) | Single GLP-1 agonist | 16% | Plateaus after 6-9 months | 11015 |
Retatrutide’s glucagon activation uniquely drives fat-burning—making it the only obesity drug that addresses both calorie intake and energy expenditure 11.
Other Benefits of Retatrutide
Beyond weight loss, Retatrutide shows promise for:
-
Type 2 Diabetes: Superior HbA1c reduction vs. insulin 10
-
Fatty Liver Disease: Up to 80% reduction in liver fat in trials 1014
-
Cardiovascular Protection: Lower blood pressure and improved lipid profiles 14
When Will Retatrutide Be Available?
-
Phase 3 trial data expected late 2025 (accelerated from early 2026) for all looking for Retatrutide for sale
-
FDA approval projected for 2026
-
Pre-orders accepted now at retatrutideforsale.shop for priority access
“With its triple-hormone action, Retatrutide could become the most effective obesity treatment ever developed.” — Eli Lilly Chief Scientific Officer 11
Who Will Be Able to Take Retatrutide?
Ideal candidates include adults with:
-
BMI ≥30 (obesity)
-
BMI ≥27 + weight-related conditions (e.g., diabetes, hypertension)
-
Inadequate results from Semaglutide/Tirzepatide
Contraindications: Pregnancy, thyroid cancer history, pancreatitis 110
How Will Patients Take Retatrutide?
-
Weekly injections via prefilled pen (similar to insulin)
-
Dosing: Starts at 2mg, escalating to 12mg for maintenance
-
Storage: Refrigerate at 2°C–8°C (36°F–46°F) 310
Pro Tip: Rotate injection sites (thigh/abdomen) to minimize bruising!
Is Retatrutide Safe?
Common side effects (typically mild/moderate):
-
Nausea (28%)
-
Diarrhea (16%)
-
Mild abdominal pain (12%) 10
No severe hypoglycemia or safety red flags emerged in trials. GI symptoms usually resolve within 4 weeks as the body adjusts 1011.
Will Insurers Pay for Patients Retatrutide Prescription?
Coverage will likely mirror other GLP-1 drugs:
-
Medicare/Medicaid: Requires BMI ≥30 + comorbidity
-
Private insurance: Prior authorization proving other treatments failed
-
Self-pay option: Competitive pricing at $355/mo (email us for a coupon: support@retatrutides.shop)
FAQ: Your Retatrutide Questions Answered
How does Retatrutide work?
It activates three hormone receptors to reduce appetite, improve insulin sensitivity, and accelerate fat breakdown 14.
Who manufactures Retatrutide?
Eli Lilly—creator of Mounjaro® and Zepbound™ 211.
How much weight can you lose?
24% body weight (avg. 58 lbs) in 48 weeks 210.
How is it administered?
Weekly subcutaneous injection 10.
Will insurance cover it?
Likely upon FDA approval for obesity (projected 2026) 1.
Why Choose retatrutideforsale.shop?
✅ Authenticity Guarantee: Third-party tested Retatrutide (99% purity)
✅ Global Shipping: Discreet, temperature-controlled delivery
✅ Medical Support: Cell Phone consultations (+1-510-854-9956)
✅ Pre-Order Discount: Reserve your 3-month supply for 15% off
What Does Retatrutide Do?
Retatrutide operates through a unique mechanism as a triple agonist, targeting the GIP, GLP-1, and GCG receptors, with a strong emphasis on GIP receptor activation [4].
Incretin hormones GLP-1 and GIP stimulate insulin secretion from pancreatic beta cells and contribute to feelings of fullness after eating, while glucagon serves a counter-regulatory function by raising blood glucose levels during fasting.
This receptor interaction leads to a comprehensive approach to metabolic regulation, significantly impacting both glycemic control and weight loss. Below is an overview of the underlying mechanisms:
- Retatrutide’s primary mechanism involves potent activation of the GIP receptor, which plays a vital role in appetite regulation by directly affecting the brain’s satiety centers. This reduces hunger, cravings, and overall food intake [8].
- Through GLP-1 receptor activation, retatrutide supports glycemic regulation and enhances satiety. GLP-1 also slows down gastrointestinal motility and delays gastric emptying, leading to increased feelings of fullness after meals [9, 10].
- Activation of the GCG receptor by retatrutide is believed to increase energy expenditure and promote fat oxidation, largely through metabolic actions in the liver. GCG receptor stimulation encourages fat breakdown and elevates metabolic rates. Additionally, it induces “beiging” of white fat, converting it into beige fat with thermogenic properties similar to brown fat, thereby boosting calorie burning and enhancing metabolism [11].
These combined mechanisms make retatrutide a promising option for treating obesity and type 2 diabetes by not only curbing calorie intake but also increasing energy expenditure, offering a dual strategy for effective weight management.
Research Applications and Benefits of Retatrutide
Outlined below you can find several key clinical trials that have demonstrated the efficacy and potential research applications of retatrutide.
Retatrutide and Weight Loss Research
As of 2024, phase 3 trials within the TRIUMPH program are in progress, exploring retatrutide’s potential for weight loss. Earlier phase 1 and phase 2 studies have shown promising results, indicating that the peptide could lead to up to a 24% reduction in body weight from baseline.
The initial human trial of retatrutide, a proof-of-concept study, took place in Singapore in 2019. This phase 1 trial involved 47 participants who were administered six different dose levels, ranging from 0.1 mg to 6 mg weekly. The study suggested potential positive effects on appetite, food intake, and other metabolic markers, alongside a favorable safety profile [4].
Following this, a larger phase 2 trial was conducted, lasting 48 weeks and involving 338 non-diabetic adults with overweight and obesity. Participants received varying doses of retatrutide, and the trial demonstrated a dose-dependent reduction in weight and improvement in cardiometabolic risk factors. Key findings included [7]:
- An 8.7% weight reduction in the 1 mg dose group
- A 17.1% weight reduction in the 4 mg group
- A 22.8% reduction in the 8 mg group
- A 24.2% reduction in the 12 mg group
All participants who received either 8 mg or 12 mg of retatrutide weekly experienced at least a 5% reduction in their initial body weight. In addition, significant reductions were observed in waist circumference, blood pressure, glycated hemoglobin, fasting glucose, insulin levels, and lipid levels, excluding HDL cholesterol.
Retatrutide and Type 2 Diabetes Research
Eli Lilly is conducting ongoing research on retatrutide’s potential to manage glycemic control and obesity in individuals with type 2 diabetes (T2D) as part of the phase 3 TRIUMPH clinical trials.
Earlier trials, including phase 1b and phase 2 studies, have shown encouraging outcomes. In a 12-week phase 1b trial, 72 adults aged 20-70 with T2D and baseline A1c levels between 7.0% and 10.5% were treated with either retatrutide, dulaglutide (a GLP-1 agonist approved by the FDA), or placebo.
By week 12, those receiving the highest dose of retatrutide (12 mg weekly) saw a significant decrease in A1c of up to 1.6% and a weight reduction of up to 19.7 pounds (8.96 kg). These results were markedly better than those seen with both dulaglutide and placebo [12].
A subsequent 36-week phase 2 trial involved 281 T2D patients receiving up to 12 mg of retatrutide weekly. Key results include [6]:
- Participants in the 12 mg group experienced a significant HbA1c reduction of 2.02% (22.07 mmol/mol) at 24 weeks and 2.16% (23.59 mmol/mol) at 36 weeks, compared to negligible change (0.01%) in the placebo group after 24 weeks.
- By the conclusion of the 36-week trial, weight loss was dose-dependent, with the 12 mg group losing 16.94% of their body weight, compared to a 3.00% reduction in the placebo group.
- Additionally, retatrutide treatment led to improved lipid profiles, including decreases in triglycerides and non-HDL cholesterol, with the 12 mg group showing significant improvement at 36 weeks compared to both baseline and placebo.
Contact Us for bULK ORDERS
Act Now: Limited Introductory Offer!
With FDA approval imminent, demand will skyrocket. Secure your supply today:
-
Choose Your Package:
-
1mg Starter Kit ($355)
-
5mg Value Bundle ($1,599)
-
10mg Premium Savings ($2,555) 3
-
-
Contact Us: +1 (510) 854-9956 for dosing guidance
-
Fast Shipping: Delivered in insulated coolers worldwide
Disclaimer: Retatrutide is currently for research use. Consult your physician before starting any new weight management program.
Live the best version of yourself! Start your transformation with the most advanced weight loss science today. ➡️ Shop Retatrutide Now